Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 17:13:292.
doi: 10.1186/1471-2407-13-292.

The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients

Kashif Shafique, Michael J Proctor, Donald C McMillan, Hing Leung, Karen Smith, Billy Sloan, David S Morrison

The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients

Kashif Shafique et al. BMC Cancer. .

Abstract

Background: As the incidence of prostate cancer continues to rise steeply, there is an increasing need to identify more accurate prognostic markers for the disease. There is some evidence that a higher modified Glasgow Prognostic Score (mGPS) may be associated with poorer survival in patients with prostate cancer but it is not known whether this is independent of other established prognostic factors. Therefore the aim of this study was to describe the relationship between mGPS and survival in patients with prostate cancer after adjustment for other prognostic factors.

Methods: Retrospective clinical series on patients in Glasgow, Scotland, for whom data from the Scottish Cancer Registry, including Gleason score, Prostate Specific Antigen (PSA), C-reactive protein (CRP) and albumin, six months prior to or following the diagnosis, were included in this study.

Results: Seven hundred and forty four prostate cancer patients were identified; of these, 497 (66.8%) died during a maximum follow up of 11.9 years. Patients with mGPS of 2 had poorest 5-year and 10-year relative survival, of 32.6% and 18.8%, respectively. Raised mGPS also had a significant association with excess risk of death at five years (mGPS 2: Relative Excess Risk = 3.57, 95% CI 2.31-5.52) and ten years (mGPS 2: Relative Excess Risk = 3.42, 95% CI 2.25-5.21) after adjusting for age, socioeconomic circumstances, Gleason score, PSA and previous in-patient bed days.

Conclusions: The mGPS is an independent and objective prognostic indicator for survival of patients with prostate cancer. It may be useful in determining the clinical management of patients with prostate cancer in addition to established prognostic markers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The modified Glasgow prognostic score and survival based on age categorie.
See this image and copyright information in PMC

References

    1. Wilt TJ. Radical prostatectomy versus observation for localized prostate cancer. NEJM. 2012;367:203–213. doi: 10.1056/NEJMoa1113162. - DOI - PMC - PubMed
    1. Castelli T, Cimino S, Magno C, Morgia G. Molecular markers for prostatic cancer. Front Biosci. 2010;2:641–656. - PubMed
    1. Huang HC, Zheng S, VanBuren V, Zhao Z. Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat. 2010;9:219–230. - PubMed
    1. Verhagen PC, Tilanus MG, de Weger RA, van Moorselaar RJ, van den Tweel JG, Boon TA. Prognostic factors in localised prostate cancer with emphasis on the application of molecular techniques. Eur Urol. 2002;41:363–371. doi: 10.1016/S0302-2838(02)00048-9. - DOI - PubMed
    1. Elsberger B, Lankston L, McMillan DC, Underwood MA, Edwards J. Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer Prostatic Dis. 2011;14:122–128. doi: 10.1038/pcan.2011.5. - DOI - PubMed